Home

Histocompatibility and Immunogenetics User Guide 2015

1. Test for HLA specific antibodies LA Antibody Test Result Positive Use HLA selected 9 platelets Good Response to Poor response to HLA selected HLA selected P actors ASS CEANN MON immune platelet destruction platelets platelets Continue Provide ABO Absent Present compatible transfusing HLA grade matches if selected platelets possible EE ial of Treat Cause Consider trial o Decide about further platelet ig transfusion based on clinical Test for HPA pistes status of the patient e g antibodies at specific antibodies 4 _ increase dose of platelets or regular intervals discontinue prophylactic Y Y transfusions Poor Response Good Response HPA Antibody Test Result Continue transfusing HLA Y Y selected platelets Positive Negative v v Provide HLA and pu dc NR HPA selected latelets consumprion P 2 ABO antibodies Template Version 07 10 08 Author s Adam West Page 15 of 41 INFORMATION DOCUMENT INF136 3 1 Effective 04 02 15 User Guide for Histocompatibility and Immunogenetics Diagnostics Services Increments with HLA class selected platelets Transfusion of selected platelets in patients with immune refractoriness result
2. selected cases only Drug induced antibody mediated thrombocytopenia e g heparin antibiotics quinine and gold Congenital and acquired thrombasthenias Neonatal alloimmune thrombocytopenia NAIT The frequency of Neonatal Alloimmune Thrombocytopenia NAIT is 1 in 1100 live births and is the most likely cause of severe thrombocytopenia in a term and otherwise healthy neonate NAIT is caused by maternal IgG alloantibodies directed against a HPA antigen present in the foetus neonate and absent in the mother Many alloantigen systems have been described but the HPA 1a antigen is clinically most important and approximately 80 of severe cases are caused by anti HPA 1a Approximately a further 15 of NAIT cases are due to HPA 5b alloimmunisation and the strategy of providing HPA 1a 5b platelets in suspected NAIT cases will therefore be successful in 95 of cases involving Caucasians NAIT due to antibodies against HPA other than HPA 1a and 5b and to isoantigens in the case of maternal platelet glycoprotein deficiencies account for approximately 596 of cases In cases where antibodies to the major HPA are not detected and there is strong clinical evidence to support a diagnosis of NAIT the maternal serum is also investigated for the presence of antibodies against private or low frequency antigens by performing a crossmatch between maternal serum and paternal platelets Investigations for NAIT The maternal serum will be screened
3. Adam West Page 38 of 41 INFORMATION DOCUMENT INF136 3 1 Effective 04 02 15 User Guide for Histocompatibility and Immunogenetics Diagnostics Services BLOOD CENTRE DETAILS Switchboard Hospital Services Centre Address Postcode Telephone FAX Telephone FAX Birmingham Vincent Drive B15 2SG 0121 278 4000 4005 4037 4039 Edgbaston Birmingham Brentwood Crescent Drive CM15 8DP 1005 1128 Brentwood Essex Filton 500 North Bristol Park BS34 7QH 0117912 5724 5783 Northway Filton 0117 921 7200 7201 Bristol Cambridge Long road Cambridge CB2 OPT 01223 58 8000 8114 8021 8121 Colindale Colindale Charcot NW9 5BG 020 8957 2700 2970 2800 2971 Road London Lancaster Ashton Road Lancaster LA1 4GT Leeds Bridle Path Leeds LS15 7TW_ 0113 820 8600 8737 8607 8738 Manchester Speke Liverpool M13 9LL 0161 423 4200 4245 4201 4358 Plymouth Grove NE2 4NQ 0191 202 4400 4505 4500 4514 Manchester Holland Drive Newcastle upon Tyne Liverpool 14 Estuary Banks L24 8RB 0151 268 7000 7001 7170 7173 Newcastle Headington Oxford Oxford John Radcliffe Hospital OX3 9BQ 01865 38 7900 7915 7963 7997 Plymouth Derriford Hospital PL6 8DH 7802 7810 Derriford Road Plymouth Sheffield Longley Lane Sheffield S5 7JN 0114 358 4800 4911 4817 4952 Southampton Coxford Road 5016 023 8035 6700 6760 6712 2060 Southampton Tooting 75 Cranmer Terrace SW17 ORB 020 3123 8300
4. Out of hours on call is provided by H amp l laboratories supporting solid organ transplant programmes 24 hours a day 365 days a year A Consultant Clinical Scientist can be contacted on your request in case of clinical emergency by contacting your local NHSBT Hospital Services HLA Selected Platelets Appropriate use of out of hours service HLA selected platelets required for early delivery on weekdays and for transfusion at weekends should always be ordered within normal laboratory Monday Friday working hours and with at least 24 hours notice Should a clinical emergency e g an episode of bleeding occur out of hours i e evenings overnight or weekends an emergency on call service for HLA selected platelet provision is available However since it is not possible to provide optimally HLA matched platelets at short notice this service should be used for clinical emergencies only and not for ad hoc routine requests If out of hours provision is requested it must be discussed and authorised by the NHSBT H amp l Consultant on call who will need to call in a staff member to process the request Selection and provision of units is likely to take a minimum of 6 hours and may take longer Whilst NHSBT will endeavour to provide a well matched unit finding a suitably matched unit at short notice may not always be possible for all patients Out of hours ordering of HLA Selected Platelets If there is an urgent clinical need for ou
5. Autoimmune thrombocytopenia A raised level of platelet associated immunoglobulin PAlg is detected in the majority of patients with autoimmune thrombocytopenia AITP However the diagnostic specificity and therefore the clinical usefulness of the PAlg test by immunofluorescence is poor Normally these investigations are only indicated if the patient s platelet count is lt 100 x 10 L The diagnostic specificity is increased if platelet glycoprotein specificity of the PAlgG can be determined by direct MAIPA assay but this assay requires a significant number of platelets which may be difficult to obtain from severely thrombocytopenic patients The detection of serum platelet autoantibodies may be indicated if the patient s platelets cannot be tested but the results may be difficult to interpret because both alloantibodies and autoantibodies may be present in the serum These investigations are recommended only in the following categories of thrombocytopenic patients e Bone marrow failure possibly combined with immune mediated thrombocytopenia e AITP patients refractory to first and second line treatment Monoclonal gammaglobulinopathies e Acquired autoantibody mediated thrombasthenia Bone marrow failure and immune mediated thrombocytopenia In some patients with thrombocytopenia due to inadequate thrombocytopoiesis antibody mediated platelet destruction may compound the thrombocytopenia e g patients with proliferative disorders s
6. INFORMATION DOCUMENT INF136 3 1 Effective 04 02 15 User Guide for Histocompatibility and Immunogenetics Diagnostics Services and patient lies with the requester such sample testing may be delayed while the laboratory confirms the sample details The requester is advised to check the identifiers and to obtain reassurance about the identifiers used for the linking between patient and sample The following information is mandatory on samples e Surname forename in ful e Date of birth pe NHS number e Date and time if pertinent of sample collection Certain exceptions apply e g anonomised samples with a unique identifier such as a GUM clinic patient test request or for non UK nationals where no NHS number exists for full details see our management process description document MPD1108 available on our website http hospital blood co uk diagnostic services hi From April 2013 the Department of Health has stipulated that NHS organisations are expected to use the NHS number consistently and therefore NHS number is requested to be provided on all samples and request forms The following additional information is also required on the request form e Requesting hospital name in full including town or city Known risk sample fe NHSorNon NHS e Diagnosis treatment Type of sample if not peripheral blood NHSBT should be informed if samples are from non NHS patients The terms and conditions of
7. 07 10 08 Author s Adam West Page 9 of 41 INFORMATION DOCUMENT INF136 3 1 Effective 04 02 15 User Guide for Histocompatibility and Immunogenetics Diagnostics Services The type of request and reason for the request must be clearly identified on the appropriate request form CONSENT To comply with the Human Tissue Act legislation Human Tissue Act 2004 it is the responsibility of the requester to ensure that any patient or donor has been informed of and has consented to the tests being requested NHSBT may ask the requester to provide a copy of this information Patients donors should be informed that any residual material of a sample may be stored as part of required archiving protocols or to enable further investigation for the benefit of the individual They also must be informed that excess surplus material may be used anonymously for quality control purposes service development or education and or ethics committee approved research projects Where patient or donor consent is required it is the responsibility of the requester to ensure the subjects of any tests have given informed consent Unless written notice is received to the contrary consent for investigations and the use of any surplus sample in scheduled purposes quality control staff development or ethics committee approved research will be assumed NHSBT H amp l laboratories have developed a series of patient information leaflets to assist healthcare profession
8. 1x10 granulocytes m of recipient surface area Severe reactions to granulocyte transfusions and failure to increment despite adequate granulocyte dosage may suggest HLA or granulocyte specific antibody formation in the recipient and in these cases referral for antibody screening is advised The investigations are similar to those described previously and where necessary HNA typing of the patient and implicated and or prospective donors will be undertaken Template Version 07 10 08 Author s Adam West Page 25 of 41 INFORMATION DOCUMENT INF136 3 1 Effective 04 02 15 User Guide for Histocompatibility and Immunogenetics Diagnostics Services CHAPTER 4D HAEMATOPOIETIC STEM CELL TRANSPLANTATION HLA typing of recipients and related or unrelated donors Incompatibility in the HLA expressed by the recipient and the stem cell donor is one of the most important factors influencing the outcome of transplantation It is therefore crucial that the most up to date techniques are used to identify these incompatibilities at the DNA level NHSBT H amp l laboratories are perfectly placed to carry out these tests since a significant number of patients prepared for haematopoietic stem cell transplant are also investigated by NHSBT for their platelet transfusion support All aspects of the service are compliant with the relevant standards for haematopoietic stem cell transplantation specifically e Standards for Histocompatibility Testing Version 6 1 Euro
9. Due to the increased risk of mislabelling when using pre printed labels addressographs samples for platelet transfusion investigations can not be accepted when the sample is labelled with an addressograph for our full sample labelling policy see MPD1108 MPD1108 section 1 4 Only labels that are printed demand and attached to the sample tube next to the patient at the time of phlebotomy are acceptable Since it is not possible to distinguish reliably between these and addressograph labels they can be accepted only from referring organisations which have informed NHSBT in writing that their sample labels are generated in an audited system and are demand printed at the time of phlebotomy Bedside generated labels need to have positive traceable identification of the sample taker but do not require a signature The laboratories may not accept referrals with inadequately completed request forms or incomplete sample labelling or where sample and request details do not match In case of a clinical emergency NHSBT may agree with the requesting consultant or laboratory scientist to proceed with the requested investigations However in such cases the issue of blood products and laboratory reports will carry an explicit warning that the three points of identification were not used for the samples and or request form and responsibility for correct identification of the sample Template Version 07 10 08 Author s Adam West Page 6 of 41
10. for HPA specific antibodies using both an immunofluorescence test and a glycoprotein specific ELISA MAIPA assay with a panel of HPA and HLA typed platelets and when appropriate paternal platelets as soon as samples arrive at the laboratory If the mother is found to have HPA specific antibodies these results will be relayed to the requester as soon as possible However laboratory results should not delay transfusion of HPA 1a 5b platelets if NAIT is suspected and there is evidence of bleeding or if the platelet count is 30 10 L Maternal and paternal blood and from infant if available will be genotyped for the HPA 1 2 3 4 5 6 9 and 15 alleles Therapy In a term neonate with normal clotting but severe thrombocytopenia lt 30 x 10 L or clinical signs of bleeding the count should be corrected as soon as possible by transfusion of HPA 1a and HPA 5b negative donor platelets without waiting for the results of the laboratory investigations HPA 1a and HPA 5b negative platelets suitable for neonatal use are available from the shelf These platelets will be compatible with maternal HPA specific antibodies in over 9096 of NAIT cases If HPA 1a and HPA 5b negative platelets are not available from stock then normal ABO and D compatible donor platelets should be administered together with high dose intravenous immunoglobulin Template Version 07 10 08 Author s Adam West Page 20 of 41 INFORMATION DOCUMENT INF136 3 1
11. gain any additional benefit from HLA HPA selected platelets compared to non HLA selected platelet units In some patients with HLA specific antibodies HPA specific antibodies may also be present requiring donor platelets compatible with both types of antibodies If compatible platelets cannot be provided either increasing the transfused dose or discontinuing prophylactic platelet support may be appropriate strategies CMV negative selected products The Advisory Committee on the Safety of Blood Tissues and Organs SaBTO position statement on the provision of cytomegalovirus tested blood components recommends that for patients other than neonates under 28 days and interuterine transfusions leucodepleated products provide adequate risk reduction for the transmission of CMV Quote from SaBTO position statement All blood components other than granulocytes in the UK now undergo leucodepletion which provides a significant degree of CMV risk reduction This measure is considered adequate risk reduction for all other patients requiring transfusion haemopoietic stem cell transplant patients organ transplant patients and immune deficient patients including those with HIV without the requirement for CMV seronegative components in addition The full report of the SaBTO CMV Steering Group may be found at https www gov uk government publications sabto report of the cytomegalovirus steering group Restricting selected products to CMV serone
12. is a precipitous fall Template Version 07 10 08 Author s Adam West Page 18 of 41 INFORMATION DOCUMENT INF136 3 1 Effective 04 02 15 User Guide for Histocompatibility and Immunogenetics Diagnostics Services in the platelet count either immediately or some days after transfusion except in case of massive transfusion should be referred for investigations and reported Patients who require blood peri operatively and in whom a severe thrombocytopenia develops will often also receive heparin However the development of thrombocytopenia in PTP is more precipitous than in HIT Heparin induced thrombocytopenia and purpura and bleeding are characteristic of PTP If PTP investigations are requested then it is important to inform the laboratory whether the patient was receiving heparin even if this was only to flush an in dwelling line Investigations Tests for HPA specific antibodies and where appropriate heparin platelet factor 4 specific antibodies will be performed Therapy High dose intravenous immunoglobulin 1 0 g kg body weight on two to three consecutive days is the treatment of choice Platelet transfusion is usually contra indicated in the acute phase Plasmapheresis needs to be considered as an additional therapy if intravenous IgG does not result in a satisfactory rise of the platelet count High dose corticosteroids are not recommended Transfusion support In the acute phase of PIP random ABO D compatible blood components a
13. laboratory Details of the ordering process can be found on the NHSBT Hospital and Science website at http nospital blood co uk library request_forms hla order_hla Order notice time It is recommended that orders are placed with sufficient time for the best available product to be selected for your patient Orders received at short notice lt 24 hours may result in units being selected only from nearby NHSBT facilities to allow delivery in the time available possibly excluding units that would lead to a better outcome for your patient Your co operation in this matter is appreciated When an order is placed for the first time for a patient the following information is required e Patient surname first name date of birth and hospital name in full E summe first name date of birth and hospital name intl e NHS number I e and D groups e HLAclass type if known e Clinical diagnosis Bleeding grade if known Hor c ME e CMV antibody status of patient e Period of expected thrombocytopenia e Contact person at hospital transfusion laboratory i Gorsem or eene eme e Consultant or Specialist Registrar responsible e Current platelet support 4 e support ooo e Patient weight In case of an allogeneic stem cell transplant the following information is required for the donor e CMV antibody status HLA class type if known ABO and D groups Template V
14. possible score 8 2 1 0 gt 50 fall and or platelet 30 50 fall and or platelet fall lt 30 and or platelet nadir 20 100 x 10 nadir 10 19 x 10 nadir 10 x 10 Clear onset between days Consistent with immunisation Platelet count fall too early 5 10 or less than 1 day if but not clear e g missing without recent heparin heparin exposure within platelet counts or onset of exposure Thrombocytopenia Timing of platelet count fall or other sequelae past 100 days New thrombosis skin necrosis post heparin bolus acute systemic reaction No other cause for platelet count fall is evident Thrombosis or other sequelae e g skin lesions OTher causes for thrombocytopenia are not evident thrombocytopenia after day 10 Progressive or recurrent thrombosis erythematous skin lesions suspected thrombosis not yet proven Possible other cause is evident None Definite other cause is present First day of immunising heparin exposure considered day 0 the day the platelet count begins to fall is considered the day of onset of thrombocytopenia it generally takes 1 3 days more until an arbitrary threshold that defines thrombocytopenia is passed BCSH Guidelines on the diagnosis and management of heparin induced thrombocytopenia second edition issue 2012 which can be found at http www bcshguidelines com 4 HAEMATOLOGY_GUIDELINES html dpage 1 amp sspage 0 amp ipage 0 gldocuments HIT_ 2012
15. service provision for the NHS by NHSBT are agreed with the National Commissioning Group Service provision for non NHS patients may be charged differently Clinical information is essential for providing the most appropriate testing and advice The quality of clinical advice will also depend on provision of adequate clinical information Absence of clinical information may lead to a delay in the processing of the sample while the requester is contacted to clarify or ascertain the type of investigations required NHSBT stores patient data on a national database and the use of hospital number without other points of identification may lead to errors as a hospital number is not unique NHS number must be used in accordance with Department of Health requirements except in cases where the individual has no NHS number or where anonymity is mandated If the address is provided then it may be entered on the patients NHSBT computer record and appear on some patient reports If the address contributes to the quality of identification then it may be used as a form of identification The sample needs to be dated as this information can be significant in determining the advice we will issue in addition the outcome of some tests may be influenced by the age of the sample KEY FACTORS THAT MAY AFFECT TESTING Sample storage time In general samples should be sent to the laboratory with minimum delay and to arrive within 24 hours of sample collection Template V
16. 8453 8352 8449 London Bold type indicates centres with H amp I laboratories PHONE FAX British Bone Marrow Registry NHSBT Filton 500 North Bristol Park Northway Filton Bristol Organ Donation and Transplantation ODT Fox Den Road 534 8RR 0117 975 7575 0117 975 7577 Stoke Gifford Bristol Template Version 07 10 08 Author s Adam West Page 39 of 41 INFORMATION DOCUMENT INF136 3 1 Effective 04 02 15 User Guide for Histocompatibility and Immunogenetics Diagnostics Services CHAPTER 8 STANDARDS GUIDELINES amp ACRONYMS British Committee for Standards in Haematology guidelines http Awww bcshguidelines com 4 HAEMATOLOGY GUIDELINES html Guidance on the microbiological safety of human organs tissues and cells used in transplantation 2011 British Transplantation Society http www dh gov uk en Publicationsandstatistics Publications PublicationsPolicyAndGuidance DH 1 21497 Guidelines for the Blood Transfusion Services in the United Kingdom 8th edition 2013 The Stationery Office London UK http www transfusionguidelines org uk index aspx Publication RB Guidance from The Royal College of Pathologists and the Institute of Biomedical Science The retention and storage of pathological records and archives 4 edition 2009 http www rcpath org publications media publications publications htm general Human Tissue Authority Codes of Practice http Awww hta gov uk legislationpolici
17. A Selected Platelets Orders for selected platelets should be made during normal working hours and wherever possible at least 24 hours notice should be given Planning in advance allows the H amp l laboratory to source the best available HLA HPA selected product for the patient The units most appropriate for selection may not be in the stock held at the local NHSBT centre and may require transport from another NHSBT centre to your local centre for issue Products which have to be supplied at short notice may not always be the optimal product for the patient Outside normal working hours platelets can be supplied for existing patients in cases of clinical urgency only SERIOUS HAZARDS OF TRANSFUSION SHOT The overall incidence of serious side effects is small when compared with number of blood components used per annum by the NHS In the majority of cases of serious reactions or hazards associated with transfusion the diagnosis is a clinical one and in some elaborate laboratory tests are required to confirm the diagnosis A suspected adverse reaction should be discussed in the first instance with a NHSBT Consultant Haematologist to agree on the best set of laboratory investigations Samples can be referred to one NHSBT laboratory and will be distributed internally Reporting adverse reactions to transfusions There is a regulatory requirement in the UK under the terms of the Blood Safety and Quality Regulations 2005 to report adverse reactions related
18. AGING AND TRANSPORT It is the responsibility of the sender to ensure that all samples are packaged in accordance with the current European agreement concerning Carriage of Dangerous Goods by Road Regulations packaging instructions 650 to prevent breakage or spillage in transit The outside of the box or package containing the samples must be clearly addressed to the H amp l Department at the appropriate Blood Centre where the testing laboratory is based including H amp l Department Diagnostic Samples as the first line of the address to prevent delivery to H amp l sample reception being delayed This may not be your local blood centre NHSBT reserves the right to refuse to handle any samples which are inappropriately packaged or labelled customers sending unsatisfactorily packaged samples will be contacted Template Version 07 10 08 Author s Adam West Page 10 of 41 INFORMATION DOCUMENT INF136 3 1 Effective 04 02 15 User Guide for Histocompatibility and Immunogenetics Diagnostics Services Pre printed address labels can be provided on request from Customer Services For advice from the Health and Safety Executive HSE packaging for posting samples see http www hse gov uk biosafety blood borne viruses transportation of infectious substances htm WHERE TO SEND SAMPLES Routine samples Accurate completion of the request form and clear labelling is essential for an effective transfer of samples to the testing laboratory Sam
19. Effective 04 02 15 User Guide for Histocompatibility and Immunogenetics Diagnostics Services Counselling and clinical questionnaires If HPA alloantibodies are detected in the maternal serum counselling should be provided to the parents about the risks to further pregnancies Details of clinical outcome are sought by the laboratory in each confirmed case of NAIT Foetal HPA genotyping in future pregnancies if the partner is heterozygous The HPA status of a foetus can be identified by analysis of genomic DNA derived from foetal blood or amniotic fluid Please discuss with one of the Consultant Haematologists before a decision for sampling is taken In general a 10ml sample of amniotic fluid depending upon gestational age or a chorionic villus biopsy is required This should reach NHSBT H amp I Filton within 48 hours of sampling To avoid the possibility of contamination it is preferable to dispatch the amniotic fluid without transferring it to a second container If amniotic fluid is transferred from one container to another precautions should be taken to avoid contamination with bacteria or with exogenous DNA Delayed engraftment of platelet lineage following stem cell transplantation Isolated failure of platelet engraftment following stem cell transplantation can be due to the presence of pre existing HPA specific antibodies in the recipient These patients should be investigated in the same way as for platelet transfusion refractoriness
20. H NHSBT CENTRES NHSBT staff can be contacted by telephone facsimile or e mail either directly using their personal details or through the centre switchboards By direct dialling All departments and senior staff can be contacted directly using direct dial numbers in this guide Our internal telephone system allows external calls to be transferred readily between departments and between centres and to mobile phones Via switchboard Alternatively all centres can be contacted 24 hours per day 7 days a week via the switchboard number during office hours and via NHSBT Hospital services outside office hours Via mobile phone Mobile phones are used by the majority of Medical amp Clinical Scientist Consultants senior scientific and managerial staff External calls to any of the blood centres in the country can be directly transferred to the mobile phones The secretariats can advise on how to contact a member of staff when he she is not at his her base centre Sending a fax All centres have central fax facilities It is therefore important that your fax is labelled clearly with the name of the person to who you wish to send it and if urgent please indicate accordingly Nearly all H amp I laboratories and all Hospital Services departments have their own fax Via e mail All H amp l staff listed can be contacted by e mail using the following address format firstname surname nhsbt nhs uk Alternatively please use hinational nhsbt nhs uk for ge
21. Haemochromatosis HFE gene C282Y and H63D 21 deficiency C O O HLA B47 21 gene 3 HLA genes associated with drug hypersensitivity Adverse Drug Reactions ADR Abacavir hypersensitivity HLA B 57 01 Allopurinol induced severe cutaneous adverse reactions Allopurinol induced severe cutaneous adverse reactions HLA B 58 01 Carbamazepine induced Stevens Johnson Syndrome HLA B 15 02 Han Chinese Thai Toxic Epidermal Necrosis SJS TEN red Syndrome HLA A31 01 Japanese Caucasian Please enquire for other testing you may require 4 Polymorphism in other immune related genes Cytokines and cytokine receptorgenes lt Cytokines and cytokine receptor genes e g TNFA IL 10 and IL 6 NKcellreceptrs CO Minor histocompatibility antigens EES Template Version 07 10 08 Author s Adam West Page 31 of 41 INFORMATION DOCUMENT INF136 3 1 Effective 04 02 15 User Guide for Histocompatibility and Immunogenetics Diagnostics Services CHAPTER 5 TECHNIQUES USED IN NHSBT H amp l LABORATORIES The following techniques are routinely used in the H amp l laboratories although further techniques are also used for the investigation of suspected thrombasthenias and further studies Please refer to the appropriate section in this guide for details regarding techniques used in specific clinical conditions Scr
22. INFORMATION DOCUMENT INF136 3 1 Effective 04 02 15 NHS Blood and Transplant HISTOCOMPATIBILITY AND IMMUNOGENETICS DIAGNOSTIC SERVICES USER GUIDE 2015 Template Version 07 10 08 Author s Adam West INFORMATION DOCUMENT INF136 3 1 Effective 04 02 15 User Guide for Histocompatibility and Immunogenetics Diagnostics Services Contents CONTENIS PAGE 2 WSrORRIGURES ae eR ALL SAM 2 Wicag omg EIER E E REPERI 2 CHAPTER 1 GENERAL INFORMATION cccccceccoceccoseccscsccacsecscsesecsesacsesassevassesassesassesasevasstsasstsasseeacseeacseeees 3 CHAPTER 2 H amp l LABORATORIES AND MANAGEMENT c ccccsceccoceccaceccacsccecsecacsccacsecacstacsesacsceucseeacseenes 4 CHAPTER 3 SAMPLE REQUIREMENTS amp REPORTING uccccccoseccoceccsceccecsccecsececsesacscacsesacseeacsesacseucsceasseeees 5 CHAPTER 4 H amp I SERVICES ccccccccececcececcscsceccsccacsesassevassesassesssacsssacsassesasacsusassasaesasassasaesasacsusaesacatsucaesecaees 13 CHAPTER 4A H amp I SERVICES RELATING TO TRANSFUSION amp TRANSFUSION REACTIONS 13 CHAPTER 4B PLATELET IMMUNOLOGY 20 CHAPTER 4C GRANULOCYTE IMMUNOLOGY Gl tette 24 CHAPTER 4D HAEMATOPOIETIC STEM CELL TRANSPLANTATION eerie 26 CHAPTER 4E SOLID ORGAN TRANSPLANTATION tenete tentent 27 CHAPTER 4F IMMUNOGENETICS HLA TYPING FOR DISEASE ASSOCIATION AND DRUG HYPERSENSITIVITY cccccccccocecescecescecescsceacscsscsesssacsasacsasacsassesssassesass
23. IVIGG within the previous 3 weeks Granulocytes are labile cells that deteriorate rapidly in vitro Consequently blood samples for direct tests must reach the GI section of the H amp l laboratory at NHSBT Filton within 24 hours of venesection The laboratory must be contacted prior to sending samples for direct tests so appropriate control samples can be arranged Neonatal alloimmune neutropenia Neonatal alloimmune neutropenia NAIN is caused by maternal alloantibodies against a granulocyte specific antigen which is present on the neutrophils of the neonate and absent from the maternal neutrophils The condition is rare lt 1 in 1000 births but may be under diagnosed Profound neonatal neutropenia places the child at risk of infectious complications The neutropenia may persist for up to Template Version 07 10 08 Author s Adam West Page 24 of 41 INFORMATION DOCUMENT INF136 3 1 Effective 04 02 15 User Guide for Histocompatibility and Immunogenetics Diagnostics Services six months In the majority of cases the maternal alloantibodies are directed against HNA Occasionally NAIN can arise due to the formation of isoantibodies against granulocyte membrane glycoproteins e g FcyRIllb CD16 which is absent in approximately 1 in 2000 of the population Clinical management consists of the use of antibiotics either prophylactically or in response to infections G CSF may be required where there is severe persistent neutropenia and infecti
24. Immunology FRM999 H amp l Granulocyte Immunology FRM1001 Request forms can be ordered directly from your local H amp I laboratory and are available to download from the NHSBT hospital website along with guidance documents on their correct completion http hospital blood co uk diaqnostic services hi hi test request forms A process of review and improvement of these forms is currently underway with new versions due out early in 2015 Requesters are advised to withdraw the previous versions of updated request forms when they are released as the use of out of date paperwork may cause errors in sample distribution SAMPLE COLLECTION AND LABELLING No specific clinical patient preparation is needed for sample collection for H amp l testing All materials used in sample collection should be disposed of safely following local sharps and clinical waste procedures A request form must accompany every sample Samples with different collection dates of different sample types e g bone marrow aspirate or peripheral blood or from different individuals including family members must each be accompanied by their own test request forms Request forms are the basis to establish the correct identification of the patient Schemes such as the SHOT scheme have shown that serious incidents are often caused by errors of a clerical nature The points of identification provided on the request form must match the information provided on the sample
25. N DOCUMENT INF136 3 1 Effective 04 02 15 User Guide for Histocompatibility and Immunogenetics Diagnostics Services hypersensitivity reactions can also be provided on request In addition tests for the detection of mutation in genes involved in the metabolism and absorption of immunosuppressive drugs are being developed and may be offered by the H amp l laboratories supporting solid organ transplant programmes All mutations are defined by using molecular DNA based typing techniques In addition to identifying HLA polymorphism H amp l laboratories also provide molecular typing for detecting mutations in other immune related genes such as minor histocompatibility mH genes natural killer NK cell receptor genes and cytokine genes Examples of HLA associated and HLA linked diseases are shown below There are additional HLA associated diseases for which a typing service can be provided Please contact the Head of Laboratory of your local NHSBT H amp l laboratory to discuss the appropriate test Genetic markers and diseases 1 HLA associated diseases Birdshot chorioretinopathy HLA A29 HLA B51 HLA B27 Rheumatoid arthritis Amino acids 70 74 on the DRB1 gene QKRAA or QRRAA Narcolepsy HLA DQB1 06 02 DQA1 01 02 Coeliac disease HLA DQA1 DQB1 Selective IgA deficiency HLA DRB1 0301 DQB1 02 Development of anti HPA 1a in NAIT HLA DRB3 01 01 NAIT neonatal alloimmune thrombocytopenia 2 HLA linked diseases
26. als to obtain informed consent for diagnostic testing The leaflets explain what happens to their samples and why the tests are undertaken In addition there is a brief explanation of Histocompatibility amp Immunogenetics investigations The leaflets are available to download from the NHSBT hospital website and or hard copies can be ordered directly from your local H amp l laboratory The link for patient information leaflets is http hospital blood co uk diagnostic services hi patient information leaflets Table 4 Summary of H amp l patient leaflets Patient Information leaflet Laboratory Histocompatibility testing for kidney transplant donors INF253 Histocompatibility testing for kidney transplant patients INF255 Local solid organ H amp l laboratory Histocompatibility testing for cardiothoracic transplant patients INF254 Histocompatibility testing for platelet transfusion patients INF256 Histocompatibility testing for stem cell transplant patients INF257 Local H amp l laboratory Histocompatibility testing for possible donors or relatives of stem INF258 cell transplant patients Immunogenetic markers and diagnosing diseases INF259 Heparin induced thrombocytopenia HIT Your background guide to HIT and the associated laboratory testing Information for mothers about neutrophil blood groups and INF261 Filton Neonatal alloimmune Neutropenia NAIN Platelet groups amp antibodies in pregnancy INF283 PACK
27. ates and red cells are banked at a limited number of blood centres These products are ordered during working hours from the H amp l laboratory at NHSBT Filton During out of hours contact the Hospital Services department at your local blood centre HPA 1a negative red cell SAG M concentrates and HPA 1a and HPA 5b negative apheresis platelet concentrates neonatal dose 1 4 of a standard adult dose are normally available off the shelf at selected centres Apheresis platelet concentrates or red cells negative for other HPA antigens need to be ordered well in advance Ideally at least 4 7 working days Additional HPA typing can be performed on request please discuss with the H amp l laboratory at NHSBT Filton HPA 1a negative platelet hyperconcentrates for use are provided from specially accredited apheresis donors who lack antibodies against red cells HLA or HPA and are CMV negative The first hyperconcentrate needs to be obtained from an RhD negative donor before the type of foetus is determined Please contact the laboratory in advance Ideally at least 7 working days for hyperconcentrates as this product has a shelf life of 24 hours and is not a stock item A request form for the ordering of platelet hyperconcentrates is available from the H amp l laboratory at NHSBT Filton The laboratory must be informed on pre and post transfusion platelet counts to ensure the effectiveness of the treatment Out of hours Selected platelets should
28. avassssassssassesassevassesassevasaesacseacseeacateacacen 30 CHAPTER 5 TECHNIQUES USED IN NHSBT H amp I LABORATORIES cccccsescececcesecceceecsceecsesecassecaeseeaees 32 CHAPTER 6 ORDERING SPECIALIST PRODUCTS eene tetas 34 CHAPTER 7 COMMUNICATING WITH NHSBT CENTRES eene tnter tents 37 CHAPTER 8 STANDARDS GUIDELINES amp ACRONYMG cccccccccecescscescsceccsceesscsessssecscsecacsuacsecstsueaesecaees 40 List of Figures Figure 1 Diagram of the management structure of the H amp l 4 Figure 2 Laboratory Investigation of Refractoriness to Platelet Transfusion 15 List of Tables Table 1 Licence accreditation NUMDETS eien rieo a a aeaaea aa aai aa ilet ania 4 Table 2 REqUEStIOM S a 6 Table 3 Summary of volumes and type of blood samples required for each test 9 Table 4 Summary of H amp l patient 10 Table 5 Summary of reporting time lssseeeeessssssesssssssesseeeeeeennn nennen nnne nnne nsn na nnns 12 Table 6 Areas of clinical medicine involving H amp l services 13 Table 7 SHOT Categories that involve the H amp l laboratories in the investigations 17 Table 8 Clinical syndromes involving plate
29. be ordered during normal working hours and special attention must be paid to planning and ordering platelets required over weekends and bank holidays in advance An out of hours service is available for unexpected clinically urgent cases only For H amp l related advice on clinically urgent cases out of hours then phone NHSBT Hospital Services at your local centre They can put you in contact with the on call H amp l Consultant Clinical Scientist For further details refer to http hospital blood co uk library request forms hla order hla Template Version 07 10 08 Author s Adam West Page 35 of 41 INFORMATION DOCUMENT INF136 3 1 Effective 04 02 15 User Guide for Histocompatibility and Immunogenetics Diagnostics Services H amp l platelet immunology services do not provide a laboratory out of hours service However HPA 1a 5b typed platelets can be issued from stock on request Requests for HPA selected neonatal platelets and HPA selected red cells should be discussed with a NHSBT Medical Consultant Phone the NHSBT Hospital Services and they can put you in contact with the on call Medical Consultant For further details refer to http hospital blood co uk library request forms hla order hpa Template Version 07 10 08 Author s Adam West Page 36 of 41 INFORMATION DOCUMENT INF136 3 1 Effective 04 02 15 User Guide for Histocompatibility and Immunogenetics Diagnostics Services CHAPTER 7 COMMUNICATING WIT
30. before proceeding Post transplant antibody monitoring is recommended for most types of solid organ transplantation For immunologically high risk transplants antibody monitoring should be intensified For any transplant if rejection is suspected a test for donor specific antibodies can confirm a diagnosis of rejection and indicate a course of management Such testing can be performed on demand but usually only during normal working hours Crossmatching If present at a high concentration patient antibodies corresponding to mismatched donor HLA can cause immediate and irreversible rejection of the transplanted organ The presence of donor HLA specific antibodies in the serum of the patient at any time prior to transplant is an indication of prior sensitisation and even in cases where these antibodies are not present at a high concentration at the time of transplant they indicate there may be an increased risk of accelerated acute or acute rejection Performing a prospective crossmatch between donor and recipient can prevent hyperacute rejection and identify some patients at risk of acute rejection A pretransplant crossmatch can therefore avoid an unintentional antibody incompatible transplant and is performed in one of two ways Firstly using donor cells peripheral blood leucocytes or leucocytes obtained from spleen or lymph nodes donor reactive antibodies can be assessed directly by either CDC complement dependent cytotoxicity or flow cytomet
31. ced Thrombocytopenia HIT 6ml clot 6ml EDTA and 6ml clot sample of drug s Contact the laboratory before referring samples 3x 6ml EDTA and 6ml clot contact laboratory Autoimmune thrombocytopenia Thrombasthenias Contact the laboratory before referring samples 6 80 ml EDTA Haematopoietic stem cell transplantation Patients NLA type Depending on WBC count Donor HLA type 6ml EDTA Local H amp l laboratory Filton Other drug related thrombocytopenias HLA specific antibodies 6ml clot Chimerism analysis 6ml EDTA Solid organ transplantation HLA type of patients donors or family amp ml EDTA members HLA specific antibodies 6ml clot Cross match live donor 40ml EDTA donor 6ml clot recipient Cross match deceased donor 6ml clot recipient Local H amp l laboratory 60ml EDTA donor OR spleen or lymph node as appropriate Newcastle require Li Heparin INSTEAD of EDTA for cross matching Auto cross match 20ml EDTA 6ml clot recipient ABO group 6ml EDTA ABO grouping can be sent directly to NHSBT RCI laboratories or H amp l laboratories can forward them to RCI on your behalf A charge will be levied for grouping NHSBT RCI User Guide can be accessed at http hospital blood co uk library user_guides index asp Immunogenetics HLA typing for disease association and drug hypersensitivity 6ml EDTA Local H amp I laboratory TYPE OF REQUEST Template Version
32. ces Autoimmune neutropenia e Neonatalallimmuneneutopenia O Severe and persistent non haemolytic febrile transfusion reactions see section 4A e e e e ransfusion related acute lung injury see section 4A e e Persistent isolated neutropenia after allogeneic bone marrow transplant Drug induced antibody mediated neutropenia e Severe reactions to granulocyte transfusions see section 4 Autoimmune neutropenia Autoimmune neutropenia AIN is a rare clinical condition caused by granulocyte autoantibodies which may occur either in children or adults but which often remains undiagnosed Autoimmune neutropenia commonly occurs in children between the ages of 6 months and 5 years where it is referred to as autoimmune neutropenia of infancy ANI although applied strictly the term infancy describes children under one year of age ANI tends to be a self limiting autoimmune condition but can last several years In adult patients AIN presents as a chronic disorder either as an isolated primary neutropenia or as a neutropenia secondary to other disorders such as rheumatoid arthritis systemic lupus erythematosus Felty s syndrome and chronic lymphocytic and large granulocytic leukaemias Granulocyte autoantibodies may target the low affinity Fc receptor for IgG FcyRIIIb or CD16 GP 56 64 kDa related antigens CD177 or CD11 18 Autoantibodies can demonstrate HNA related specificity and therefore the sera are screene
33. could have affected the quality of patient care Such incidents and near misses often require immediate action and you are advised to discuss these with an NHSBT Medical Consultant or a senior laboratory scientist at your local blood centre Serious events must be reported to the SABRE scheme CHAPTER 2 H amp l LABORATORIES AND MANAGEMENT There are six laboratories in the H amp l Function with approximately 190 members of staff The laboratories are located at NHSBT Birmingham Filton Bristol Colindale North London Newcasile Sheffield and Tooting South London and each is directed by a Consultant Clinical Scientist Figure 1 highlights the management structure of the H amp l Function Figure 1 Diagram of the management structure of the H amp l Function Dr Andrea Harmer National Head of H amp l Services Management Group Dr Martin Howell Tim Key Dr Anthony Poles Prof David Briggs Dr Deborah Sage Dr Colin Brown Head of Laboratory Head of Laboratory Head of Head of Laboratory Head of Laboratory Head of Laboratory Newcastle Sheffield Laboratory Filton Birmingham Tooting Colindale H amp l H amp l H amp l H amp l H amp l H amp l NHSBT H amp l laboratories support haematopoietic stem cell and solid organ transplant programmes at hospitals throughout England The H amp l laboratory at Filton provides platelet immunology and granulocyte immunology services nationally The H amp l laboratory at Colindale works in co operation wi
34. d against a panel of granulocytes typed for the human neutrophil antigens HNA On occasion it is important to determine whether antibodies with HNA specificity are autoimmune or alloimmune in origin This can be achieved by typing the patient for the relevant HNA and or performing a direct granulocyte immunofluorescence test Immune complexes may also bind to granulocytes There is no simple procedure to distinguish between immune complexes and pan reactive autoantibodies Investigations The serum will be investigated by the indirect granulocyte immunofluorescence chemiluminescence tests using granulocytes from donors typed for HNA 1 2 3 4 and 5 These investigations are only indicated if the patient has a neutrophil count lt 2 0 x 10 L and the results will affect clinical management Referrals without a stated neutrophil count or if the neutrophil count is gt 2 0x10 L or if inadequate clinical information is provided may not be investigated If the serum test is negative a direct granulocyte immunofluorescence test for IgG and IgM can be arranged with the laboratory but only in cases were there is strong evidence to support the diagnosis and where the result will influence clinical management Elevated granulocyte bound immunoglobulins have been found in patients who lack demonstrable serum autoantibodies Direct tests cannot be performed on patients with a neutrophil count lt 0 4 x 10 L or if the patient has received G CSF or
35. d in aggregation studies depending on the dose of agonist used and BSS without the striking morphology of giant platelets has been reported Monoclonal platelet glycoprotein antibodies against CD41 61 CD42 and CD49 and flow cytometry provide a sensitive method to confirm the diagnosis However many laboratories only use a single monoclonal antibody for each CD marker which limits the diagnostic sensitivity null mutants will be identified but more subtle mis sense mutations may remain undetected Consequently the patients platelets are tested with a large panel of the relevant monoclonal antibodies to improve diagnostic sensitivity These tests can only be performed after discussion with the H amp l laboratory at Filton If the diagnosis of GT BSS or inherited collagen receptor deficiency is confirmed advice regarding transfusion support will be provided In addition direct sequencing of the coding regions of the relevant genes BSS GPIbB GP IX GT TGA2B and ITGB3 is now available please contact H amp l laboratory at NHSBT Filton Template Version 07 10 08 Author s Adam West Page 23 of 41 INFORMATION DOCUMENT INF136 3 1 Effective 04 02 15 User Guide for Histocompatibility and Immunogenetics Diagnostics Services CHAPTER 4 GRANULOCYTE IMMUNOLOGY There are seven clinical syndromes for which services are provided as shown in Table 10 Table 10 Clinical syndromes involving granulocyte immunology Gl servi
36. development of certain diseases can be identified by testing performed by the NHSBT H amp l laboratories Examples of HLA genes associated with disease include HLA B27 with ankylosing spondylitis and specific HLA DQ genes with coeliac disease CD In CD only certain HLA DQ heterodimers are able to present the gluten peptides to immune cells and initiate the response which leads to CD Complete testing of both DQ alpha and DQ beta genes is required in order to identify the implicated alleles The HFE gene associated with hereditary haemochromatosis is another gene found in the MHC region Two mis sense mutations in the gene a cysteine282tyrosine and histidine63aspartic acid have both been shown to be associated with the development of disease Between 80 90 of haemochromatosis cases are homozygous for the tyrosine282 codon In addition up to 78 of individuals heterozygous for both mutations may exhibit evidence of iron overload A DNA based technique that allows the simultaneous identification of both HFE mutations has been developed and validated by participation in UKNEQAS HLA genes have also been found to be markers of some drug hypersensitivity responses HLA B 57 01 is associated with hypersenitivity to the anti retroviral agent Abacavir The H amp l laboratories routinely provide HLA B 57 01 testing and testing for other HLA alleles implicated in drug Template Version 07 10 08 Author s Adam West Page 30 of 41 INFORMATIO
37. e apps Template Version 07 10 08 Author s Adam West Page 37 of 41 INFORMATION DOCUMENT INF136 3 1 Effective 04 02 15 User Guide for Histocompatibility and Immunogenetics Diagnostics Services H amp l HEADS OF LABORATORIES CONTACT DETAILS be Name Role Location Regional Local Fnet code code Dr Andrea Harmer National Head of H amp l Sheffield 0114 358 Debra Marples PA Sheffield 0114 358 Prof David Briggs Head of Laboratory Birmingham 0121 278 Pauline Hall PA Birmingham 0121 278 Dr Colin Brown Head of Laboratory Colindale 020 8957 Usha Mistry PA Colindale 020 8957 Dr Anthony Poles Head of Laboratory Filton 0117 921 Tuarita Lawson PA Filton 0117 921 Tim Key Head of Laboratory Sheffield 0114 358 Claire Mcfarlane PA Sheffield 0114 358 Dr Martin Howell Head of Laboratory Newcastle 0191 202 Alison Campbell PA Newcastle 0191 eter 202 Dr Deborah Sage Head of Laboratory Tooting 020 3123 8567 Jackie Davis PA Tooting 020 3123 8387 LABORATORY CONTACTS DETAILS H amp l Centre Contact name Lab Selected Fax service products H amp I PI GI Filton Anthony Poles 0117921 7473 001 902 57833 5728 5731 H amp l Colindale Colin Brown 020 8957 2811 2812 2819 2973 H amp l Newcastle Martin Howell 0191 202 4475 4410 4525 4564 H amp l Sheffield Tim Key 0114 358 4914 4839 4830 4806 4850 8347 8488 Template Version 07 10 08 Author s
38. e made However when the platelet count recovers during therapy a discrepancy between bleeding tendency and platelet count may be apparent In such cases platelet aggregation studies may be consistent with Glanzmann s thrombasthenia Bernard Soulier syndrome or a collagen receptor deficiency of the acquired type PAlg and autoantibody specificity investigations are important in these rare cases to confirm the true pathophysiology Glanzmann s thrombasthenia Bernard Soulier syndrome collagen receptor deficiencies Homozygous or compound heterozygous mis sense non sense mutations or deletions insertions in genes encoding platelet membrane receptors can cause congenital bleeding disorders of the platelet type Classic examples are Glanzmann s thrombasthenia GT and Bernard Soulier syndrome BSS which are both rare autosomal recessive disorders with an absence or reduced expression of the platelet allBB3 integrin GPllb Illa CD61 41 and the Von Willebrand Factor receptor complex GPIb IX V CD42 respectively Reduced expression of the platelet collagen receptors GPla lla or 0281 integrin and GPVI have also been reported as a cause of congenital thrombasthenia Investigations The diagnosis of GT BSS and collagen receptor deficiencies is made on bleeding phenotype by the results of platelet aggregation studies and in classic BSS on platelet count and morphology However mis sense mutations associated with a mild phenotype might be misse
39. e results of crossmatch tests can be highly complex particularly in patients with historically high levels of antibodies which have since decreased Specialised interpretation of these results is necessary to determine their clinical significance Advice on specific cases will be provided by the H amp l Consultant Clinical Scientist as required BTS BSHI Guidelines for the detection and characterisation of clinically relevant antibodies in allotransplantation 2010 which can be found at http www bshi org uk html guidelines html Template Version 07 10 08 Author s Adam West Page 28 of 41 INFORMATION DOCUMENT INF136 3 1 Effective 04 02 15 User Guide for Histocompatibility and Immunogenetics Diagnostics Services Pretransplant antibody removal Desensitisation Pretransplant antibody removal undertaken to allow transplantation in crossmatch positive cases Antibody incompatible Transplantation AiT is termed desensitisation Incompatibility is either due to ABO mismatch or preformed HLA donor specific antibodies DSA Desensitisation is achieved by extracorporeal antibody removal using various techniques During the desensitisation process antibody removal should be monitored so that the effectiveness of the process can be assessed and a safe level of residual antibody can be determined before the transplant can proceed During the early post transplant phase DSA can be re synthesised and cause rejection Early detection of an emerg
40. eening for cytotoxic and non cytotoxic HLA specific antibodies Screening for HLA class and class ll specific antibodies is performed using one or more of a number of different techniques including the classic microlymphocytotoxicity test an ELISA based technique Luminex and flow cytometric based methods If the screening is positive further tests are carried out to identify the specificity of the antibodies Molecular HLA class and class Il typing HLA class A B C and class Il DR DQ DP DNA typing is carried out using a variety of DNA based techniques including sequence specific priming SSP and sequence specific oligonucleotide probing SSOP Furthermore HLA class and II high resolution typing used to provide an HLA type at the allele level for bone marrow peripheral blood or cord blood stem cell transplant patients and their related or unrelated donors is done using DNA Sequence Based Typing SBT All molecular techniques used for HLA class and class Il molecular typing have been fully validated as part of the participation in national and international histocompatibility workshops and quality assurance schemes Crossmatching Different techniques are used by the laboratories which includes microlymphocytotoxicity test and flow cytometric based methods Short Tandem Repeat STR analysis for the detection of chimerism Fluorescently labelled PCR primers are used to amplify STR loci resulting in an STR profile for
41. ersion 07 10 08 Author s Adam West Page 34 of 41 INFORMATION DOCUMENT INF136 3 1 Effective 04 02 15 User Guide for Histocompatibility and Immunogenetics Diagnostics Services Ordering of HPA selected platelets and red cells non refractory All orders for HPA selected platelets and red cells for non refractory patients during normal working hours should be made directly to the H amp l laboratory at NHSBT Filton When an order is placed for the first time for a patient the following information is required e Patient surname first name date of birth and hospital number or patient address e NHS number e Hospital name e ABO and D groups e Contact person at hospital transfusion laboratory Consultant or specialist registrar responsible e e Red cell specific antibodies present 1 0 E e Type quantity of product required date and time needed HPA typed products The following HPA typed products are available HPA 1a negative red cells e HPA anegaliveredcells _ e HPA 1a and HPA 5b negative apheresis platelet concentrates for neonates neonatal dose e HPA 1a HPA 5b negative platelet hyperconcentrates for foetal use from accredited donors e Red cells or platelet concentrates typed for other HPA antigens These must be ordered at least 7 days in advance These products may not be available off the shelf HPA 1a and 5b negative typed platelet concentr
42. ersion 07 10 08 Author s Adam West Page 7 of 41 INFORMATION DOCUMENT INF136 3 1 Effective 04 02 15 User Guide for Histocompatibility and Immunogenetics Diagnostics Services Sample storage and transportation temperature In general samples should be stored and transported at ambient temperature It is important to collect samples into the correct tubes Please ensure the correct anticoagulant usually EDTA or no anticoagulant clot is used It is also important to supply adequate volumes of blood to allow completion of testing Sample types and volumes are listed in Table 3 In addition if the patient s platelet and or white cell count is low or affected by condition and or drug regime this may affect the outcome of some tests For further details please refer to NHSBT H amp l test request forms and information in Table 3 Summary of volumes and type of blood samples required for each test or contact your local H amp l laboratory for help and advice Volume and types of sample Refer to Table 3 for the volumes and type of blood samples required for each test For further information look at the request forms via the NHSBT hospital website Contact the relevant laboratory when referring samples of infants under 6 months to discuss the minimum sample requirements Template Version 07 10 08 Author s Adam West Page 8 of 41 INFORMATION DOCUMENT INF136 3 1 Effective 04 02 15 User Guide for Histocompatibility and Immunoge
43. esandcodesofpractice codesofpractice cfm International Standards for Cellular Therapy Product Collection Processing and Administration 5th edition 2012 FACT JACIE http www factweb org forms store ProductFormPublic search action 1 amp Product_productNumber 62 1 Renal Association Guidelines Assessment of the Potential Kidney Transplant Recipient 5 edition 2011 http www renal org Clinical GuidelinesSection AssessmentforRenalTransplantation aspx Standards for cord blood collection processing testing banking selection and release 5 edition 2013 NetCord FACT http www factweb org forms store ProductFormPublic search action 1 amp Product_productNumb er 62 Standards for Histocompatibility Testing Version 6 1 2013 EFI http www efiweb eu index php id 102 All links verified 06 01 2015 Template Version 07 10 08 Author s Adam West Page 40 of 41 INFORMATION DOCUMENT INF136 3 1 Effective 04 02 15 User Guide for Histocompatibility and Immunogenetics Diagnostics Services AiT Antibody incompatible Transplantation AIN Autoimmune Neutropenia AITP Autoimmune Thrombocytopenia ALI Acute Lung Injury ANI Autoimmune Neutropenia of Infancy ARDS Acute Respiratory Distress Syndrome BBMR British Bone Marrow Registry BSS Bernard Soulier Syndrome CPA Clinical Pathology Accreditation CIT Cold Ischemia Time DDITP Drug Dependent Immune Thrombocytopenia DH Department of Healt
44. gative units severely reduces the number of units available and may result in a less beneficial unit being selected for your patient Template Version 07 10 08 Author s Adam West Page 13 of 41 INFORMATION DOCUMENT INF136 3 1 Effective 04 02 15 User Guide for Histocompatibility and Immunogenetics Diagnostics Services Alloimmunisation against platelets Alloimmunisation is defined as the development of an immune response against alloantigens In some transfusions this immune response may result in the production of HLA and or HPA specific antibodies Refractoriness is the failure to obtain satisfactory responses to transfusions of platelets from unselected but ABO compatible donors A proportion of but not all alloimmunised patients will become refractory It is generally accepted that as a consequence of universal leucocyte depletion of all blood components the rate of alloimmunisation has dropped to approximately 10 25 However the precise incidence is influenced by a number of factors including pregnancies and the number of transfusions Non immune mechanisms are an important cause of refractoriness and have been shown to cause transfusion failure in a significant group of patients on prophylactic platelet transfusion support Platelet refractoriness Platelet refractoriness is defined as a failure of the platelet count to increase by greater than 10 x 10 L at between 1 and 24 hours after the transfusion of an adult dose of ABO compat
45. h DSA Donor Specific Antibodies EFI European Federation of Immunogenetics FCXM Flow Cytometric Crossmatch FFP Fresh Frozen Plasma GCLT Granulocyte Chemiluminescence Test GI Granulocyte Immunology GIFT Granulocyte Immunofluorescence Test GLP Good Laboratory Practice GMP Good Manufacturing Practice GT Glanzmann s Thrombasthenia H amp l Histocompatibility amp Immunogenetics HIT Heparin Induced Thrombocytopenia HLA Human Leukocyte Antigen HNA Human Neutrophil Antigen HPA Human Platelet Antigen HTA Human Tissue Authority MHRA Medicines and Healthcare products Regulatory Agency MAIGA Monoclonal Antibody Immobilisation of Granulocyte Antigen MAIPA Monoclonal Antibody Immobilisation of Platelet Antigen NAIN Neonatal Alloimmune Neutropenia NAIT Neonatal Alloimmune Thrombocytopenia NHSBT National Health Service Blood and Transplant NHFTR Non Haemolytic Febrile Transfusion Reaction ODT Organ Donation and Transplantation PAlg Platelet Associated Immunoglobulin Pl Platelet Immunology PIFT Platelet Immunofluorescence Test PTP Post Transfusion Purpura SHOT Serious Hazards of Transfusion SOP Standard Operating Procedure STR Short Tandem Repeat SSOP Sequence Specific Oligonucleotide Probing SSP Sequence Specific Priming Transfusion Associated Graft Versus Host Disease Transfusion Related Acute Lung Injury UK NEQAS United Kingdo
46. he patient post transfusion This allows assessment of the chimeric status of the patient post transfusion Samples required for this analysis would be a patient pre transfusion sample if no DNA has previously been isolated from this patient then a buccal scrape would provide cells for DNA isolation an EDTA blood sample from the donor and an EDTA sample from the patient post transfusion CHAPTER 4E SOLID ORGAN TRANSPLANTATION The H amp l laboratories support organ transplantation SOTx by identifying and characterising immunological risk factors that determine outcome and provide advice accordingly These risk factors are the degree of human leucocyte antigen HLA mismatch between donor and recipient and specific sensitisation to non self HLA A 24 hour on call service operates every day of the year for deceased donor HLA typing and crossmatching of local patients for renal and where appropriate cardiothoracic transplantation Our aim is to work in partnership with the transplant and clinical units as part of the overall transplant team Accountability for service provision development and governance lies with the local H amp l Consultant Development of local transplant policies particularly allocation rules should include liaison with the Head of Laboratory Clinical and scientific advice from an H amp l Consultant Clinical Scientist relating to solid organ transplantation is also always available HLA typing for SOTx In the UK deceased d
47. ible platelets gt 240 x 10 L platelets Refractoriness to random donor platelets can be of non immune or immune cause or a combination of both When to request HLA class selected platelets The majority of patients with immune refractoriness are best supported with platelet transfusions that are either HLA selected or HLA compatible between the donor and patient HLA selected platelets are collected by apheresis and specific donors may have to be called to donate these platelets for a specific patient The provision of this service is time consuming and expensive and should be reserved for those patients who really need them The following criteria should be met e Exclusion of non immune causes of refractoriness e Positive screen for HLA class or HPA specific antibodies or both e Refractoriness to an ABO compatible platelet concentrate on two occasions Template Version 07 10 08 Author s Adam West Page 14 of 41 INFORMATION DOCUMENT INF136 3 1 Effective 04 02 15 User Guide for Histocompatibility and Immunogenetics Diagnostics Services Figure 2 Laboratory Investigation of Refractoriness to Platelet Transfusion Laboratory Investigation of Refractoriness to Platelet Transfusion Patients likely to receive multiple platelet transfusion Assess transfusion response Poor response to random donor platelets 2 or more occasions
48. illin beta lactams glycopeptide Le Quinine and quinidine O e Goldsals 0000000000000 jJ Heparin induced thrombocytopenia HIT Heparin Induced Thrombocytopenia HIT An ELISA test for heparin platelet factor 4 specific antibodies can be of use in patients with a clinical diagnosis of HIT and in whom continued anticoagulation is required In such patients prompt withdrawal of heparin and alternative anticoagulation with recombinant hirudin or an alternative heparinoid should be considered without waiting for laboratory results The BCSH guidelines for the management of heparin induced thrombocytopenia describe a scoring system based on the 4Ts that be used to assess the probability of a patient developing HIT The 4Ts e Thrombocytopenia Timing of platelet count fall Thrombosis causes for thrombocytopenia are not evident 1 111 Table 9 should be used to assess the probability that a patient has HIT A score of 6 8 means there is a high probability of HIT 4 5 means the probability is intermediate 0 3 means there is a low probability If you think your patient has HIT stop heparin and switch to an alternative antithrombotic agent Table 9 Assessment of the probability that a patient has HIT Estimating the probability of HIT the 4Ts Probability of HIT score Points 0 1 or 2 for each of 4 categories maximum
49. in platelet concentrates derived from pooled buffy coats Investigations The logistics of TRALI investigations are complicated and time consuming When referring a suspected case of TRALI full clinical details should be provided in order to assess the likelihood of the reaction having been due to TRALI Clinical details should include nature of transfusion reaction and time in relation to transfusion components transfused including donation numbers treatment given including ventilation and clinical response Leucocyte antibodies are generally against HLA class antigens but HLA class ll or specific antibodies may also be implicated Initial investigations will be performed with fresh donor samples It is therefore important that donation numbers of all implicated units blood platelet concentrates FFP in the 24 hours preceding TRALI presentation are provided Pre and post transfusion serum samples from the patient should be provided together with the date and time the samples were taken The investigations for TRALI are done at the H amp l laboratory at NHSBT Filton The investigations aim to identify the presence of e class and class II specific cytotoxic antibodies e class and class ll specific non cytotoxic antibodies e Granulocyte specific antibodies If donor leucocyte alloantibodies are detected then appropriate tests for the presence absence of the antigen or allele in the patient donor
50. ing response allows effective treatment and management of rejection Frequent DSA monitoring with fast turn around times are therefore essential for a safe desensitisation programme Rapid DSA testing requires significant resources and scientific staff need to be available on demand Therefore if laboratory support for AiT is required there must be a formal agreement with the laboratory to allocate the necessary resources Effective communication between the laboratory and the transplant unit is essential for these high risk procedures to be undertaken with safety A reliable and unimpeded sample transport system must be established Tests ABO Antibody levels will be monitored in terms of titre of IgG and IgM using reagent red cells of the donor group Transplantation would not normally proceed if the titre of the corresponding antibody exceeds 1 8 It is therefore very important to test immediately before the transplant is to proceed In NHSBT ABO testing is carried out by Red Cell Immunohematology RCI who will make a separate charge for this service HLA AIT The amount of desensitisation required will depend on the pre treatment levels of DSA The highest levels of DSA will be cytotoxic and a cytotoxic titre assay should be performed to measure these against donor lymphocytes CDC crossmatch The strength of non cytotoxic DSA should be assessed by a flow cytometric crossmatch FCXM DSA levels and specificity are most effectively mon
51. inical The clinical presentation is indistinguishable from the Acute Respiratory Distress Syndrome ARDS or its less severe form acute lung injury ALI The aetiology of TRALI is complex and is difficult to distinguish from ARDS ALI on the basis of clinical symptoms and tests TRALI is therefore a diagnosis made by Template Version 07 10 08 Author s Adam West Page 17 of 41 INFORMATION DOCUMENT INF136 3 1 Effective 04 02 15 User Guide for Histocompatibility and Immunogenetics Diagnostics Services exclusion where other causes of ARDS ALI are not apparent and where there has been a recent transfusion of blood or other plasma containing blood products Although rare TRALI is a significant cause of transfusion associated morbidity and mortality The risk of the latter can be reduced by early recognition of the cause and optimal treatment Some cases were considered after review not to be TRALI illustrating the difficulty of making a positive clinical diagnosis of the condition However in many cases TRALI was thought either likely or possibly to have contributed to the patient s death Leucocyte antibodies in the donor plasma generally cause this syndrome Even a small volume of plasma containing leucocyte antibodies such as that found in SAG M red cell concentrates is able to precipitate a reaction On rare occasions TRALI can also be caused by leucocyte antibodies in the recipient or by immune complexes of leucocyte antigens and antibodies
52. international registries can also be initiated For cord blood stem cells the UK cord blood registry and other international cord blood registries are searched The H amp l laboratory will co ordinate the donor searches and the request for confirmatory typing of potential donors They will also advise on the final selection of the most suitable donor and will liaise on behalf of the requester with relevant donor registry Graft information advisory service GIAS compatibility assessment Graft Information Advisory Service GIAS and compatibility assessment is an integral part of haematopoietic stem cell transplantation support from our laboratories Our services are always supported by the highest standards of advice from Consultant Clinical Scientists and their staff Clinical Scientist staff will support the identification and selection of donors most advantageous to your patients This encompasses the whole process from diagnosis to transplant and beyond with transplant and antibody monitoring and supply of specialised selected blood products when needed Chimerism investigation for post transplant monitoring Fluorescently labelled PCR primers are used to amplify STR loci resulting in an STR profile for the patient pre transplant the donor and the patient post transplant This allows assessment of the chimeric status of the patient following transplantation Pre transplant sample from the patient and an EDTA blood sample or bone marrow asp
53. irate post transplant is required for STR analysis A donor sample is also required Where possible if sample size allows both patient pre transplant and donor DNA will be stored at laboratories where HLA typing has been performed If stored sample is not available it is possible to isolate DNA from the buccal Template Version 07 10 08 Author s Adam West Page 26 of 41 INFORMATION DOCUMENT INF136 3 1 Effective 04 02 15 User Guide for Histocompatibility and Immunogenetics Diagnostics Services cells of the patient with the resulting DNA being the equivalent of a pre transplant sample Your local H amp l laboratory will be able to advise Data has demonstrated that increased sensitivity can be achieved in the investigation of chimerism when isolating specific cell lineages e g T cells This may be particularly relevant for patients with certain malignancies where cell lineage isolation prior to STR analysis can detect changes in chimeric status otherwise undetectable by whole blood analysis NHSBT H amp l laboratories are able to perform STR analysis on specific cell lineages e g T cells the myeloid compartment and B cells Again an EDTA blood sample from the patient post transplant is required for this analysis STR analysis is also a critical diagnostic tool in the investigation of transfusion associated graft versus host disease TAGVHD STR profiles can be established for the patient pre transfusion the implicated donor and t
54. itored using antigen coated beads in an immunofluorescence assay e g Luminex 1 These assays are significantly more sensitive than previous methods and our experience shows that reducing DSA to undetectable by desensitisation is rarely achieved An assessment of a safe level for transplantation needs to be determined for each case by discussing with the H amp l Consultant A pre transplant crossmatch should always be performed normally a FCXM is sufficient Frequency of testing During antibody removal pre and post treatment serum samples should be sent directly to the laboratory Throughout the early post transplant phase up to three weeks daily serum samples should be taken and sent to the laboratory Early post transplant antibody resynthesis can be treated with antibody removal if accompanied by rejection and this should be monitored as above From week three approximately weekly serum samples should be taken for antibody testing until a stable antibody profile is established usually 3 5 months Thereafter monthly samples should be taken to year 1 followed by six monthly samples Additional Services In addition to performing and reporting tests there are certain Supporting and administrative elements provided by the laboratory which may constitute part of the H amp l service required for a transplant programme It is important that close liaison is maintained between the laboratory and the clinical transplant units in order to establi
55. ive 04 02 15 User Guide for Histocompatibility and Immunogenetics Diagnostics Services Table 5 Summary of reporting time SERVICE REPORT 90 within HLA type Immunological refractoriness to platelets HLA antibody screen 7 working days Platelet antibody specificity e g NAIT 5 working days HIT 5 working days Platelet Immunology HIT urgent result 1 working day Other drug induced thrombocytopenia Foetal HPA typing Granulocyte Immunology Gl All tests 21 working days Haematopoietic Stem Cell Transplantation HLA type class and 7 working days HSCT HLA type class and 1 Solid organ transplantation HLA antibody screen Urgent result 1 day Immunogenetics All tests 5 working days This must be discussed with the laboratory ahead of sending the sample HPA 15 antibody testing may require 21 working days depending on donor availability COMPUTER RECORDS AND REPORTS Computer records The H amp l laboratories are supported by national computer systems Hematos PULSE on which patient and donor data are stored NHSBT computer systems are registered under the Data Protection Act Access to the database is on a need to know basis for clinical care purpose only and confidentiality is respected at all times Reporting NHSBT H amp l now has electronic reporting capabilities for those requesters with NHS network access This system is based on the Sunquest ICE elect
56. latelet suspension medium and to blood transfusions by removing the plasma proteins by washing If severe febrile reactions are not resolved by altering of the component specification then tests for leucocyte and platelet alloantibodies may be of use If any of these antibodies are present in the patient then reactions may be remedied by better matching In such rare and complex cases it is recommended to run investigations for HLA class and class Il HNA and HPA specific antibodies in parallel Samples should be referred to the local H amp l laboratory Tests for leucocyte and HPA alloantibodies have a low diagnostic specificity for NHFTR and the reactions may persist even if better selected blood or platelets are provided Template Version 07 10 08 Author s Adam West Page 19 of 41 INFORMATION DOCUMENT INF136 3 1 Effective 04 02 15 User Guide for Histocompatibility and Immunogenetics Diagnostics Services CHAPTER 4B PLATELET IMMUNOLOGY There are six clinical syndromes for which services are provided as shown in Table 8 Table 8 Clinical syndromes involving platelet immunology services Neonatal alloimmune thrombocytopenia Post transfusion purpura refer to chapter 4a Refractoriness HPA only tested for after HLA antibody investigation refer to chapter 4a Delayed engraftment of platelet lineage following bone marrow transplantation investigated only after HLA antibody investigation Autoimmune thrombocytopenia
57. let immunology 20 Table 9 Assessment of the probability that a patient has 22 Table 10 Clinical syndromes involving granulocyte immunology services 24 Template Version 07 10 08 Author s Adam West Page 2 of 41 INFORMATION DOCUMENT INF136 3 1 Effective 04 02 15 User Guide for Histocompatibility and Immunogenetics Diagnostics Services CHAPTER 1 GENERAL INFORMATION THIS GUIDE The NHSBT H amp l function offers an integrated package of services testing and clinical advice across the whole H amp l field from a network of six laboratories Working as an integral part of NHSBT we offer hospitals an unrivalled portfolio of testing advice and support in transplantation supply of selected blood products and Immunogenetics This guide outlines the Histocompatibility amp Immunogenetics H amp l services provided by NHSBT and will be of use to consultants and other medical nursing and scientific staff in transfusion laboratories haematology departments transplant units and other healthcare environments with patients requiring our services The guide contains information about the organisation of services and contact details for key members of staff and other information to enable healthcare staff to access services on behalf of their patients QUALITY STATEMENT The H amp l functi
58. m National External Quality Assurance Scheme Author s Adam West Template Version 07 10 08 Page 41 of 41
59. ne is known to cause drug dependent antibody formation via this hapten mechanism Other drugs e g B lactams have been reported to elicit the formation of antibodies Alternatively some drugs induce the formation of true autoantibodies which are able to bind granulocytes in the absence of any drug These drugs e g levamisole appear to alter the homeostasis of the immune system resulting in autoimmunity against granulocytes in a small number of patients The investigation of cases with drug dependent antibodies can be complicated Furthermore some antibodies have been reported to only be detected at specific concentrations of the drug by specific techniques or in the presence of drug metabolites Please phone the H amp l laboratory at NHSBT Filton before referring such cases Investigations The patient serum sample is investigated for granulocyte specific antibodies by granulocyte immunofluorescence tests using a panel of granulocytes typed for HNA 1 to 5 in the presence and absence of the implicated drug The referring centre must provide a sample of the implicated drug s Further investigations may require the provision of anti coagulated blood from the patient Granulocyte transfusion reactions An increment in granulocyte count greater than 0 5 x 10 L is not always achieved in profoundly granulocytopenic recipients by granulocyte transfusions An incremental count would be expected to be seen with granulocyte doses of at least
60. neric enquiries For safety reasons attachments with incoming e mails will be scanned and can be placed in quarantine The sender and the addressee will be informed automatically when this safety mechanism is triggered NBSBT maintains several websites including http www nhsbt nhs uk www blood co uk for donors and http nospital blood co uk index asp for healthcare professionals where information regarding all aspects blood donation blood stock levels and information about services can be found Customer Services If you have a query regarding the services provided by NHSBT you can also contact one of our Customer Services Managers Each centre has a Customer Services Manager who works closely with local consultants and scientists The Customer Services Managers are responsible for understanding the requirements of service users and for acting as a central point for contacts for technical operational and financial issues For contact details refer to http hospital blood co uk contact us How to enrol as a donor Should you wish to enrol as a donor or want information on blood or platelet donation and donation session times please contact NHSBT national donor call centre on 0300 123 2323 open 24 hours per day 7 days per week or visit our website www blood co uk or download our session searcher app for smartphones and tablets available for both android and apple at http www blood co uk giving blood where can i go smartphon
61. netics Diagnostics Services Table 3 Summary of volumes and type of blood samples required for each test SAMPLE REQUIREMENTS LABORATORY Transfusion amp transfusion reactions investigation of Platelet eee refractoriness 6ml EDTA and 6ml clot NB this investigation requires an HLA type and HLA antibody screen Follow up testing of platelet refractoriness 6ml clot Local H amp l laboratory HLA type 6ml EDTA HLA antibody screen 6ml clot Pre transfusion sample Transfusion Related Acute Lung Injury 2 x 6ml clot amp 2 x 6ml EDTA patient Filton TRALI Donation numbers of all blood products transfused lt 24hrs before event Transfusion Associated Graft Versus Host Disease TA GVHD Post transfusion purpura PTP 6ml EDTA and 6ml clot Filton Granulocyte immunology Discuss sample requirements with H amp Consultant Local H amp l laboratory Maternal 6ml EDTA 6ml clot Paternal 6ml EDTA Neonate 0 5 1ml ETDA Neonatal Allolmmune Neutropenia NAIN for initial screen not crossmatch Autoimmune neutropenia 6ml clot smaller volumes permissible for infants FIOR Drug related neutropenia 6ml clot sample of drug s Contact the laboratory before referring samples Platelet immunology Foetal Neonatal Allolmmune Maternal 6ml EDTA 6ml clot Thrombocytopenia NAIT for initial screen Paternal 6ml EDTA not crossmatch Neonate 0 5 1ml ETDA Heparin Indu
62. ng Typing for HNA HNA 1 2 3 4 and 5 are typically performed either by serology HNA 2 or polymerase chain reaction by sequence based typing PCRSBT HNA 1 3 4 5 Template Version 07 10 08 Author s Adam West Page 33 of 41 INFORMATION DOCUMENT INF136 3 1 Effective 04 02 15 User Guide for Histocompatibility and Immunogenetics Diagnostics Services CHAPTER 6 ORDERING SPECIALIST PRODUCTS Ordering blood products All standard blood products are ordered from NHSBT Hospital Services which can be contacted 24 hours per day each day of the year Use direct dial numbers during normal working hours and for out of hours Medical and scientific advice is available 24 hours a day Refer to chapter 7 for contact details Specialist products issued by the H amp l function HLA selected platelets are ordered directly from your local NHSBT H amp l laboratory during laboratory operating hours 9 00 5 00 This is also the case for platelet refractory patients with both HLA amp HPA specific antibodies and HPA specific antibodies only The laboratory staff can be contacted directly and will liaise on your behalf with the respective NHSBT Hospital Services and Transport departments to organise delivery either directly to your hospital or via your local blood centre Ordering of HLA or HPA amp HLA selected platelets To order HLA or HLA amp HPA selected platelets in the first instance contact your local NHSBT H amp l
63. on Investigations Serum investigations are similar to those for autoimmunity but a crossmatch of maternal serum versus paternal granulocytes may be performed to determine the presence of low frequency granulocyte specific antibodies if initial investigations are negative In the event of HLA specific antibodies being present the serum sample will be further investigated by a glycoprotein capture ELISA MAIGA assay The maternal and paternal HNA type will be determined In serologically confirmed cases of NAIN involving HNA specific antibodies the zygosity of the father of the child should be determined so that the risk to future pregnancies can be assessed Persistent isolated neutropenia after bone marrow transplant Both HNA alloantibodies and autoantibodies can cause persistent isolated neutropenia after bone marrow transplantation Granulocyte immunology investigations can be informative in such cases Investigations are similar to those described above Drug induced antibody mediated neutropenia A wide range of drugs can cause immune mediated neutropenia However these idiosyncratic reactions only occur in a small number of patients There are several mechanisms for drug induced antibody mediated neutropenia One established mechanism occurs when membrane glycoproteins bind to the drug to form a hapten This causes the formation of antibodies which only bind to granulocytes in the presence of the drug Quinine and its stereoisomer quinidi
64. on in common with other NHSBT services is committed to quality as outlined in our Quality Policy document All work is carried out within the framework of a documented quality system according to good laboratory and good manufacturing practice GLP GMP in compliance with the Blood Safety and Quality Regulations Human Tissue Quality and Safety for Human Application Regulations TQSR EU Organ Donation Directive EUODD the Data Protection and Freedom of Information Acts Techniques and procedures are validated described in standard operating procedures SOP and conducted by staff whose proficiency is regularly monitored NHSBT Quality managers carry out regular audits to establish and improve the level of GLP and GMP compliance These complement external licensing and accreditation inspections by the Medicines and Healthcare Products Regulatory Agency MHRA UKAS Clinical Pathology Accreditation CPA European Federation of Immunogenetics EFI Human Tissue Authority Care Quality Commission CQC and other relevant accreditation bodies The Head of Function Heads of Laboratories laboratory and support staff have continued to standardise practice and strive for a consistent and high quality service Procedures are developed to work according to the principles of clinical governance All laboratories within the function participate in external quality assurance schemes such as UKNEQAS and where appropriate in international worksho
65. onor kidneys are currently allocated though NHSBT Organ Donation amp Transplantation ODT using matching algorithms in which HLA match is a key factor Thus all patients are required to be HLA typed before being placed on the transplant waiting list Donors will be HLA typed and then allocated to recipients on the list based on factors including HLA match the matching schemes for organ allocation can be found on the ODT web site at http www organdonation nhs uk about transplants organ allocation Because of the extreme variability of HLA in the population most patients will receive a graft from a donor mismatched to some degree for HLA The greater the degree of mismatch the greater risk of immunological rejection however by modifying the immunosuppression this may be compensated HLA matching is normally not a primary consideration in other forms of transplantation cardiothoracic liver etc Graft failure is often associated with immunological sensitisation to mismatched donor HLA and this can severely limit the possibility of retransplantation if this were to be an option It is the responsibility of the clinical teams to inform the laboratory if a patient has been exposed to a specific sensitisation event and provide a test sample Routine testing for HLA specific antibodies HLA specific sensitisation is best investigated by serological analysis for antibodies Any exposure to non self HLA such as from transplantation transfusion or p
66. pdf Template Version 07 10 08 Author s Adam West Page 22 of 41 INFORMATION DOCUMENT INF136 3 1 Effective 04 02 15 User Guide for Histocompatibility and Immunogenetics Diagnostics Services It is requested that the 4T test be applied to all patients for whom samples are referred for heparin dependent antibody investigation and the score entered on the request form In selected circumstances additional information may be requested regarding some referrals In cases where patients have received a transfusion in the previous 12 days followed by a precipitous drop in platelet count a diagnosis of post transfusion purpura PTP should also be considered Other drugs Investigation of the presence of platelet specific antibodies against other drugs is time consuming and positive control drug dependent antibody samples are typically not available Reporting time will be extended since these investigations are not routine It is the referring centre s responsibility to provide samples of the implicated drug s preferably in an aqueous form Without such samples the drug dependent antibody test will not proceed THROMBASTHENIA Acquired thrombasthenia Platelet autoantibodies generally target epitopes on GPIlb IlIla CD41 GPIb IX V CD42 GPla lla CD49 or GPVI and in some patients the autoantibody may target the ligand binding site of these glycoproteins in cases with severe thrombocytopenia a diagnosis of AITP is likely to b
67. pean Federation for Immunogenetics EFI October 2013 HLA antibody screening for haematopoietic stem cell transplant patients For certain patients undergoing allogeneic stem cell transplantation it is advisable to perform HLA class and class 1 antibody screening well in advance As the use of alternative donors e g HLA mismatched adult donors haploidentical donors and cord blood for HSCT is increasing the relevance of HLA specific antibodies on donor compatibility becomes critical Knowledge of the patient s antibody status is of value when selecting the final donor for transplant and assessing overall risk Platelet transfusion support may also be complicated in HLA antibody positive patients Unrelated donor searches of the stem cell and cord blood registries NHSBT provides a facility for searching national and international unrelated stem cell and cord blood registries for patients requiring haematopoietic stem cell transplantation where no HLA compatible family member has been identified Requests from transplant centres for searches of registries should be made via the local NHSBT H amp l laboratory A search via NHSBT H amp l laboratories will automatically be referred to the Anthony Nolan Trust ANT who on behalf of the aligned registries will undertake a search of volunteer unrelated donors held on the British Bone Marrow Registry BBMR Welsh Bone Marrow Donor registry WBMDR and Anthony Nolan Registry When required searching of
68. ples for non urgent testing can be given to NHSBT blood delivery driver via the hospital transfusion laboratory For investigations not available from your local blood centre it is advisable to send samples directly to the H amp l laboratory conducting the testing Samples for platelet immunology and granulocyte immunology investigations should be sent directly by first class post to the H amp l laboratory at Filton Refer to Table 2 for further details Urgent samples For urgent testing of samples please phone the testing laboratory and discuss the arrangements for sending the samples Urgent samples should be transported directly from the hospital transfusion laboratory transplant unit or requesting clinician to the blood centre where tests are performed Packages must be clearly labelled including H amp l Department Diagnostic Samples to ensure samples do not go astray Blood Centre location maps can be provided on request or from the NHSBT website for couriers carrying urgent samples REPORTING TIME In 90 of cases NHSBT aim to issue reports for investigations such as general H amp l platelet immunology DNA based investigations e g HLA HFE and other immune polymorphism typing within five working days from receipt of the samples in the laboratory A longer turnaround time may apply to other investigations HLA specific antibody test reports for patients refractory to platelet transfusion will normally be issued within seven working day
69. ps In some instances this participation extends to the provision of source material devising the exercises or acting as a reference laboratory COMPLIMENTS and COMPLAINTS NHSBT is committed to continuously improving the quality and range of services provided and welcomes any comments or suggestions from the service users There is always the risk of failures in any service delivery and it is essential that these be reported to ensure the causes can be fully investigated to reduce the risk of recurrence help improve the service and ensure compliance with clinical governance policies specific forms have been made available to every service user for this and can be found on the NHSBT website at http hospital blood co uk customer services complaints compliments and feedback Please do not hesitate to discuss complaints with either your Customer Services Manager or the relevant Head of Laboratory We always strive to provide a satisfactory response to any complaint However if you are unhappy with the handling of your complaint then please contact the Head of Service Delivery or the Lead Quality Specialist for H amp l Template Version 07 10 08 Author s Adam West Page 3 of 41 INFORMATION DOCUMENT INF136 3 1 Effective 04 02 15 User Guide for Histocompatibility and Immunogenetics Diagnostics Services Complaints must be clearly separated from communication about serious hazards of transfusion SHOT or near misses which have or
70. re advised HPA compatible blood and platelets must be used if a patient requires transfusion after recovery SEVERE NON HAEMOLYTIC FEBRILE TRANSFUSION REACTIONS The incidence of Non Haemolytic Febrile Transfusions Reactions NHFTR and of rigors have both reduced as a consequence of the introduction of universal leucocyte depletion However it remains a common consequence of transfusing blood or blood products In the majority of cases pre medication with paracetamol may alleviate symptoms If severe and when combined with other features such as hypotension then bacterial contamination of blood products especially platelet concentrates must be considered and an NHSBT Medical Consultant must be contacted urgently for advice and investigations Non haemolytic febrile and allergic transfusion reactions with an immunological cause Apart from bacterial contamination severe febrile transfusion reactions may be caused by immunological reactions Severe immunological reactions can be of the allergic anaphylactic type with rashes wheezing or dyspnoea If febrile reactions recur and are refractory to paracetamol and corticosteroids other causes should be considered It is advised that such cases be discussed with a NHSBT Medical Consultant The straightforward method for prevention of both types of reactions is to alter the specification of the blood product i e reactions to platelet transfusions may be simply resolved by replacement of the plasma by p
71. regnancy can stimulate the production of HLA specific antibodies These can vary in their potency and persistence depending on the nature and number of stimulating events but represent a significant risk of graft failure All patients on a transplant waiting list should therefore be monitored regularly for the presence of HLA specific Template Version 07 10 08 Author s Adam West Page 27 of 41 INFORMATION DOCUMENT INF136 3 1 Effective 04 02 15 User Guide for Histocompatibility and Immunogenetics Diagnostics Services antibodies For prospective kidney and cardiothoracic transplant patients the recommendation is that each patient should be tested at least three monthly and after each potential sensitising event All antibody positive sera will be characterised for specificity for all known HLA A B C DR DP and DQ antigens For some sera i e those from highly sensitised patients reacting with over 8096 of the donor population this may require successive testing by increasingly sensitive and specific techniques n such cases the completion of testing may take significantly longer than for less complex cases For certain highly sensitised patients pre transplant antibody removal desensitisation may offer the only possibility of being transplanted NHSBT H amp l laboratories can support such procedures but because it is excessively labour intensive for the laboratory this must be discussed and planned with the Head of the Laboratory
72. ronic reporting system and is named SpICE Specialist Services ICE SpICE will reduce significantly the time taken for reports to be available to requesters once they have been authorised for release all reports should be visible to those with access to them on the system within one hour of the report being authorised as opposed to being delayed by the printing and postal delivery process Hard copy reports will continue to be sent in addition to the electronic reports until NHSBT is informed by requesters that they are no longer required The basic principle for hard copy reports is for them to be sent to the requester Please contact the laboratory if you require different hard copy reporting arrangements When requested urgent reports can be faxed to a requester but the requester will be asked to fax this request on headed paper as proof of identity in order to protect patient confidentiality More information about SpICE including a user guide presentation and FAQ can be found on the NHSBT Hospital and Science website at http hospital blood co uk diagnostic services sp ice browser Antibody cards For patients with clinically relevant platelet HPA and or neutrophil HNA allo antibodies or cell specific iso or drug dependent antibodies an antibody card will be issued for the patient SpICE will enable hospitals to access patient antibody cards for printing if required Information leaflets will be sent for patients with a diagno
73. rvals until the SHOT questionnaire is completed Following investigation of the incident by the reporting hospital and where appropriate by the blood services the reporter is required to submit a confirmation report to MHRA via SABRE which effectively closes the case provides an assessment of the likelihood of the reaction being due to the blood component and details where appropriate any corrective and preventative actions put in place to reduce the likelihood of the event recurring Further information SHOT www shotuk org 0161 423 4208 MHRA www mhra gov uk 020 3080 6000 Current SHOT reporting categories and laboratory flowchart may be found at http www shotuk org sabre The SHOT reactions that involve the H amp l laboratories in the investigations are in Table 7 Table 7 SHOT Categories that involve the H amp l laboratories in the investigations Type of SHOT reaction Abbreviation Post transfusion purpura PTP Transfusion associated graft versus host disease TA GVHD Transfusion related acute lung injury TRALI Severe non haemolytic febrile transfusion reactions NHFTR ATR Classified as Acute transfusion Reaction by SHOT TRANSFUSION ASSOCIATED GRAFT VERSUS HOST DISEASE TA GVHD Transfusion Associated Graft Versus Host Disease TA GVHD is usually fatal but almost entirely preventable complication of transfusion Patients at risk of this complication have been clearly defined as have gro
74. ry the latter being a more sensitive assay Secondly using the results of HLA antibody specificity tests on the recipient together with the HLA type of the donor a virtual crossmatch VXM can be performed Essentially the VXM predicts the result of a donor cell based crossmatch and is dependent on a comprehensive knowledge of the specificity of any detected antibody and its potential reactivity with a donor of given HLA type Virtual crossmatching is routinely used in cardiothoracic transplantation where time does not allow for a cell based crossmatch to be completed In renal transplantation virtual crossmatching may be used for a well defined population of potential recipients but is not currently recommended for highly sensitised patients A prospective crossmatch is required or recommended in renal pancreatic cardiothoracic and small bowel transplantation The choice of pretransplant crossmatch can vary with transplant type and should be controlled by local policies guided by national policies guidelines and accreditation standards Where the prospective crossmatch was a virtual crossmatch a retrospective donor leucocyte confirmatory crossmatch should always be done The time taken to perform the leucocyte crossmatch is usually between 3 and 6 hours of laboratory time A VXM can usually be completed in 30 minutes but this does require the on call H amp l scientist to go to the laboratory in order to review the patient s serological history Th
75. s but preliminary reports of HLA antibody positivity may be available sooner upon discussion with the local laboratory Drug dependent antibody screening other than heparin induced thrombocytopenia may take up to 20 working days as these investigations often require additional studies Reports for complex cases e g requiring multi stage testing family or combined donor recipient reports requiring collation of test results from multiple samples may take longer than five days from receipt of the first test request sample to the generation of the final report In 9096 of cases NHSBT aim to issue reports for granulocyte immunology investigations within 14 working days from receipt of the samples in the laboratory If further specific investigations are required the turnaround time may extend to 21 working days Blood samples referred for foetal HPA typing will be tested and the results reported within 3 working days of receipt of the sample Amniocytes referred for foetal HPA typing will be tested and the provisional results reported within 3 working days of the receipt of the sample A final report is only issued after typing of cultured amniocytes Depending on the number of viable cells a further 21 days may be required before sufficient cells are available for confirmatory typing to be completed Details are summarised in Table 5 Template Version 07 10 08 Author s Adam West Page 11 of 41 INFORMATION DOCUMENT INF136 3 1 Effect
76. s in a significantly improved post transfusion increment in 60 70 of patients The H amp l laboratory needs to collect increment data to identify units that obtain satisfactory results from transfusions The platelet count should be measured 1 hour after completion of the transfusion but can be obtained after 10 minutes 1 The laboratory can then identify those donors that are most beneficial to patients and assign further units accordingly Transfusion failure with HLA class selected platelets may be due to co existing non immune causes of refractoriness HPA alloantibodies platelet autoantibodies drug dependent platelet antibodies and potent anti A or anti B antibodies If increments with HLA class selected platelets are poor the case should be discussed with an H amp l Consultant Clinical Scientist Assays for the detection and identification of HPA specific antibodies may then be recommended In refractory patients with active bleeding a dual investigation strategy of simultaneous investigations for HLA and HPA specific antibodies may be indicated HLA amp HPA Selected Platelets For patients with HPA as well as HLA class specific antibodies attempts will be made to provide dual selected platelets This may not be possible if the platelet specific antibodies are against high frequency HPA alloantigens In this case HPA selected platelets alone may be provided to determine if these give a satisfactory increment Ordering HLA amp HP
77. samples and request forms can be forwarded to RCI by your local H amp l laboratory although this may contribute to the turnaround time of the test an additional charge will be made for this grouping service by RCI Further information about NHSBT RCI services can be found in their user guide at http hospital blood co uk library user guides index asp Where a local transplant waiting list is required this can also be maintained and distributed by the laboratory The laboratory database has the functionality to identify patients from whom we have not received sufficiently recent samples We can send written reminders to the clinical units as part of our service Failure to provide up to date serum samples can compromise the chance of a patient receiving a transplant Out of hours Out of hours on call is provided by H amp l laboratories supporting solid organ transplant programmes 24 hours a day 365 days a year A Consultant Clinical Scientist can be contacted on your request in case of clinical emergency via your local Hospital Services department CHAPTER 4F IMMUNOGENETICS HLA TYPING FOR DISEASE ASSOCIATION AND DRUG HYPERSENSITIVITY Genetic variations mutations or polymorphism within genes are now known to occur frequently throughout the human genome Amongst these are mutations in genes located on or in proximity to the major histocompatibility locus MHC on the short arm of chromosome 6 Genetic markers determining the risk for the
78. sh good working relationships with the medical and nursing staff Senior laboratory staff should attend relevant clinical and audit meetings The H amp l laboratory should play a major role within the multidisciplinary team involved in the provision planning and development of clinical transplantation services Template Version 07 10 08 Author s Adam West Page 29 of 41 INFORMATION DOCUMENT INF136 3 1 Effective 04 02 15 User Guide for Histocompatibility and Immunogenetics Diagnostics Services The laboratory maintains a database of successive test results for all patients and their donors From this we can establish and review each patient s immunological history and where necessary provide advice on general transplant suitability and specific advice regarding risk of individual transplants For patients on the national renal transplant waiting list at Organ Donation and Transplantation ODT the H amp l laboratory will be responsible if required for updating the ODT database with HLA typing and antibody data and collating other information as requested In addition registration of new patients with ODT can be performed by the H amp l laboratory To do this additional information such as demographics virology status and blood group must be given to the laboratory Blood grouping of donors and recipients can be undertaken by NHSBT RCI samples should be sent to your local NHSBT RCI department with a test request form alternatively
79. sis of NAIT NAIN or HIT Antibody cards are not issued for patients with HLA specific antibodies Template Version 07 10 08 Author s Adam West Page 12 of 41 INFORMATION DOCUMENT INF136 3 1 Effective 04 02 15 User Guide for Histocompatibility and Immunogenetics Diagnostics Services CHAPTER 4 H amp l SERVICES Services are provided to support the diagnosis and or treatment of a variety of conditions and are relevant in the following areas of clinical medicine shown in Table 6 Table 6 Areas of clinical medicine involving H amp l services HATES H amp l service relating to transfusion and transfusion reactions Platelet refractoriness and provision of HLA HPA selected platelets Investigations of serious hazards of transfusion SHOT latelet Immunology 4B P Granulocyte Immunology GI 4C Haematopoietic Stem Cell Transplantation HSCT 4D Solid organ transplantation 4E Immunogenetics 4F CHAPTER 4A H amp l SERVICES RELATING TO TRANSFUSION amp TRANSFUSION REACTIONS PLATELET REFRACTORINESS AND THE PROVISION OF HLA HPA SELECTED PLATELETS Platelet transfusion refractoriness may result from immune or non immune platelet destruction The identification of platelet refractoriness due to HLA HPA specific antibodies is important to enable allocation of these specialised products to those patients who will benefit from them Patients with non immune platelet refractoriness will not
80. t of hours transfusion in patients already receiving HLA selected platelets orders should be sent to Hospital Services Any orders for HLA selected platelets received by Hospital Services will be treated as emergency orders and will be passed on to an on call H amp l Consultant to be dealt with as an emergency request The emergency service is available week nights from 5 00 p m to 9 00 a m and weekends from 5 00 p m on Friday to 9 00 a m on Monday and all day on bank holidays Please send routine orders directly to your local H amp l laboratory to be processed during normal laboratory hours Mon Fri 9 00 a m 5 00 p m The process for ordering HLA selected products is described on the NHSBT Hospital and Science website http hospital blood co uk library request_forms hla order_hla CHAPTER 3 SAMPLE REQUIREMENTS amp REPORTING SAMPLE REQUIREMENTS For sample requirements refer to Table 3 REQUEST FORMS There are five request forms available which are shown in Table 2 Template Version 07 10 08 Author s Adam West Page 5 of 41 INFORMATION DOCUMENT INF136 3 1 Effective 04 02 15 User Guide for Histocompatibility and Immunogenetics Diagnostics Services Table 2 Request forms mu Requsttom H amp l Diagnostic and transfusion laboratory FRM745 3B H amp I Organ Transplant recipients and donors FRM1008 3C H amp l Haematopoietic Stem Cell Transplantation FRM1010 H amp I Platelet
81. th the British Bone Marrow Registry BBMR carrying out high throughput typing NHSBT s blood donors who have volunteered to become stem cell donors The H amp l laboratory at Colindale also performs the typing and registration of stem cell donors for the BBMR and cord blood donor units collected by the NHS Cord Blood Bank NHS CBB The HLA data is then submitted to Netcord and to Bone Marrow Donors Worldwide BMDW All NHSBT H amp I laboratories are accredited by Clinical Pathology Accreditation UK Ltd CPA and European Federation for Immunogenetics EFI for the clinical services they provide Table 1 License accreditation numbers UKAS CPA EFI MHRA MIAIMP 03 GB 020 980 BE25224 site 21251 03 GB 015 985 BE25224 site 698080 03 GB 002 998 BE25224 site 90677 03 GB 003 997 BE25224 site 90667 03 GB 004 996 BE25224 site 90668 Sheffield North 2823 03 GB 006 994 BE25224 site 21292 MIAIMP Department of Health and MHRA Register of Holders of Manufacturer s Authorisations for Investigational Medicinal Products MIAIMP 2013 Template Version 07 10 08 Author s Adam West Page 4 of 41 INFORMATION DOCUMENT INF136 3 1 Effective 04 02 15 User Guide for Histocompatibility and Immunogenetics Diagnostics Services LABORATORIES OPENING HOURS The core working hours of the laboratories are between 9 00 a m and 5 00 p m from Monday to Friday excluding bank holidays OUT OF HOURS Solid Organ Transplant programmes
82. that positive reactions are heparin dependent rather than autoantibodies Additional testing using different ELISA assays is available for use in specific cases where initial test results are ambiguous Template Version 07 10 08 Author s Adam West Page 32 of 41 INFORMATION DOCUMENT INF136 3 1 Effective 04 02 15 User Guide for Histocompatibility and Immunogenetics Diagnostics Services Screening for granulocyte specific antibodies The granulocyte immunofluorescence test GIFT with a flow cytometric endpoint the granulocyte chemiluminescence test GCLT and the Monoclonal Antibody Immobilisation of Granulocyte Antigen MAIGA assay are used together with a HNA typed granulocyte panel to facilitate the detection and identification of antibodies directed against granulocyte membrane glycoproteins These techniques are usually performed as indirect tests using patient serum Direct immunofluorescence tests using the patient s granulocytes can be performed in certain cases but these investigations are restricted by the patient s neutrophil count and the necessity to test the samples within 24 hours of venesection A direct test will only be performed after tests for granulocyte serum antibodies have been performed and must be arranged in advance with the H amp l laboratory at NHSBT Filton Granulocyte Immunology investigations can be prolonged compared to other investigations because granulocytes are labile cells and cannot be stored for testi
83. the patient pre transplant the donor and the patient post transplant This allows assessment of the chimeric status of the patient following transplantation or during investigation of suspected TaGVHD NHSBT H amp l laboratories are able to perform STR analysis on specific cell lineages e g T cells the myeloid compartment and B cells Screening for platelet specific antibodies The Platelet Immunofluorescence Test PIFT with a flow cytometric endpoint and the Monoclonal Antibody Immobilisation of Platelet Antigen MAIPA assay together with a panel of HPA typed platelets are used to facilitate the detection and identification of antibodies directed against platelet membrane glycoproteins Both techniques are usually performed as an indirect test using patient serum but both tests can also used as a direct test to detect immunoglobulins bound to patient s platelets and identify platelet glycoprotein specificities Typically the direct MAIPA assay is only performed for specific patients after discussion with the H amp l laboratory at NHSBT Filton Molecular typing for HPA alleles 1 2 3 4 5 6 9 and 15 Determination of HPA alleles 1 2 3 4 5 6 9 and 15 is performed using sequence based typing PCRSBT Heparin Induced Thrombocytopenia ELISA tests for heparin dependent platelet factor 4 specific antibodies are performed in suspected cases of Heparin Induced Thrombocytopenia HIT Excess heparin is added to the test system to confirm
84. to transfusion The Medicines and Healthcare products Regulatory Agency MHRA has been appointed the Competent Authority on behalf of the Secretary of State to administer the regulations and has developed a web based haemovigilance reporting system called SABRE Serious Adverse Blood Reactions and Events to facilitate reporting All Trusts in the UK should be registered with the MHRA and must submit a notification report to them as soon as possible following a reaction At the time of reporting there is the opportunity to tick a box which allows the report to be transmitted to SHOT the Serious Hazards of Transfusion confidential enquiry allowing them access to the report details All trusts should be registered to report to SHOT s web based database known as Dendrite Reporting to SHOT is strongly encouraged and is professionally mandated by accreditation bodies such as CPA Clinical pathology Accreditation O Connell B Lee EJ and Schiffer CA The value of 10 minute post transfusion counts Transfusion 1988 28 66 67 Template Version 07 10 08 Author s Adam West Page 16 of 41 INFORMATION DOCUMENT INF136 3 1 Effective 04 02 15 User Guide for Histocompatibility and Immunogenetics Diagnostics Services After selecting the SHOT option in SABRE an automated e mail is generated containing a link to the SHOT database Dendrite This SHOT questionnaire can then be completed online Automated reminders will be sent at regular inte
85. uch as chronic lymphocytic leukaemia CLL or stem cell transplant recipients Reactive megakaryocytopoiesis is a diagnostic cornerstone of AITP but is not diagnostic if platelet autoimmunity is present in addition to bone marrow infiltration failure A PAlg test and determination of autoantibody specificity may be of use AITP patients refractory and first or second line treatment For AITP patients for whom third line treatment is considered a PAlg test direct MAIPA assay and or determination of antibody specificity may be indicated Monoclonal gammaglobulinopathies Patients with a paraprotein in their serum Monoclonal gammaglobulinopathies of unknown significance MGUS myeloma secretory lymphoma and a profound and unexplained thrombocytopenia should be investigated to determine whether the paraprotein is platelet reactive Although rare reactivity of paraproteins with platelets and thrombocytopenia has been reported and is the platelet equivalent of cold haemagglutinin disease Template Version 07 10 08 Author s Adam West Page 21 of 41 INFORMATION DOCUMENT INF136 3 1 Effective 04 02 15 User Guide for Histocompatibility and Immunogenetics Diagnostics Services Drug dependent immune thrombocytopenia DDITP Many drugs are associated with thrombocytopenia For some drugs there is firm evidence that the thrombocytopenia is antibody mediated We recommend testing for DDITP for the following drugs e e Antibiotics penic
86. ups not considered to be at risk Components implicated are red cells platelet concentrates fresh plasma and granulocytes At risk patients should carry the card issued by the Department of Health which can be obtained from NHSBT Hospital Services and receive gamma irradiated blood components The dose of gamma irradiation should be a minimum of 2500 cGy to any part of the blood component Investigations In supporting the clinical diagnosis laboratory testing to demonstrate mixed chimerism is important TA GVHD is the result of engraftment and proliferation of alloreactive donor lymphocytes in the recipient Inflammation and tissue damage follow Tests for short tandem repeats on patient DNA and on DNA from pinch skin biopsy samples from affected and non affected sites will be required to establish the presence of infiltrating donor lymphocytes in the TA GvHD skin lesions and to unequivocally identify cells of donor and patient origin TRANSFUSION RELATED ACUTE LUNG INJURY TRALI Transfusion Related Acute Lung Injury TRALI is a serious complication of transfusion which usually occurs within 6 hours of a transfusion episode and is characterised by symptoms and signs of dyspnoea cyanosis hypoxaemia and pulmonary oedema and in the absence of other causes such as cardiac insufficiency and fluid overload Chest X ray shows characteristic pulmonary infiltrates None of the clinical features are specific to TRALI and the diagnosis is essentially cl
87. will be performed to determine whether the patient is positive for the cognate antigen Even if this is the case there is a good chance that the incompatibility is by chance and is not the cause of ARDS ALI TRALI does not always ensue even when a patient is positive for the cognate antigen Future transfusions There is no clear evidence on the best transfusion support policy for patients who have experienced TRALI However the notion that in addition to donor leucocyte antibodies patient factors may contribute to the risk of TRALI is generally accepted Therefore in a patient who has experienced a TRALI it is recommended not to use plasma containing blood products from female donors FFP cryoprecipitate platelet concentrates as the chance of leucocyte antibodies being present is greater in this group POST TRANSFUSION PURPURA PTP Post transfusion purpura PTP is a rare but serious transfusion reaction occurring 5 to 12 days after the transfusion of blood A sharp decline in the number of confirmed PTP cases has been observed since the introduction of universal leucocyte depletion PTP mainly occurs in women and HPA 1a specific antibodies are generally detected However other HPA specific antibodies can also cause Severe thrombocytopenia occurring immediately after the transfusion of whole blood a platelet concentrate or fresh frozen plasma can be caused by potent HPA antibody in the transfused plasma All cases in which there

Histocompatibility and Immunogenetics User Guide 2015

Contents

Download Pdf Manuals

Related Search

Related Contents